Published ahead of print on October 29, 2004, doi:10.1164/rccm.200405-579OC
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 183-187, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200405-579OC
Neuropeptide Y and Leptin in Patients with Obstructive Sleep Apnea Syndrome
Role of Obesity
Antonia Barceló,
Ferran Barbé,
Elena Llompart,
Mónica de la Peña,
Joaquin Durán-Cantolla,
Antoni Ladaria,
Margalida Bosch,
Lourdes Guerra and
Alvar G. N. Agustí
Serveis de Anàlisis Cliniques and Pneumologia, Hospital Universitari Son Dureta, Institut Universitari de Ciencies de la Salut, Palma de Mallorca; and Servicio de Neumologia, Hospital Txagorritxu, Vitoria-Gasteiz, Spain
Correspondence and reprint requests should be addressed to Ferran Barbé, M.D., Servei de Pneumología, Hospital Universitari Son Dureta, C/ Andrea Doria 55, 07014 Palma de Mallorca. E-mail: fbarbe{at}hsd.es
Neuropeptide Y (NPY) and leptin are two peptides involved in the regulation of body weight, energy balance, and sympathetic tone. This study investigates the independent role of apneas and obesity on NPY and leptin plasma levels in patients with obstructive sleep apnea syndrome (OSAS). To this end we compared their values in 23 obese (body mass index > 30 kg/m2) and 24 nonobese (body mass index < 27 kg/m2) patients with OSAS, and in 19 obese and 18 nonobese control subjects without OSAS. Patients who used continuous positive airway pressure for more than 4 hours/night were reexamined 3 and 12 months later. We found that NPY levels were increased (p < 0.01) in patients with OSAS independently of obesity. Leptin levels were also increased in OSAS but this was mostly associated to obesity. Continuous positive airway pressure treatment reduced NPY levels in all patients and leptin levels only in nonobese patients (p < 0.01). We concluded that NPY and leptin plasma levels are increased in patients with OSAS. Yet, whereas the former appear independent of obesity, the latter are mostly associated with obesity.
Key Words: cardiovascular risk • continuous positive airway pressure • obesity • sympathetic nervous system
This article has been cited by other articles:
|
|
|
|
 
L. Lavie and P. Lavie
Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link
Eur. Respir. J.,
June 1, 2009;
33(6):
1467 - 1484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R H Straub, G Pongratz, H Hirvonen, T Pohjolainen, M Mikkelsson, and M Leirisalo-Repo
Acute cold stress in rheumatoid arthritis inadequately activates stress responses and induces an increase of interleukin 6
Ann Rheum Dis,
April 1, 2009;
68(4):
572 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Vorona
Sleep, Sleep Disorders, and the Endocrine System
ACCP Sleep Med Brd Rev,
January 1, 2009;
4(0):
163 - 184.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Veasey
Peptide amidation: a push me, don't pull you for the morbidities in sleep apnea
J Appl Physiol,
January 1, 2009;
106(1):
3 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Lopez-Jimenez, F. H. Sert Kuniyoshi, A. Gami, and V. K. Somers
Obstructive Sleep Apnea: Implications for Cardiac and Vascular Disease
Chest,
March 1, 2008;
133(3):
793 - 804.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tasali and M. S. M. Ip
Obstructive Sleep Apnea and Metabolic Syndrome: Alterations in Glucose Metabolism and Inflammation
Proceedings of the ATS,
February 15, 2008;
5(2):
207 - 217.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. S. Capdevila, L. Kheirandish-Gozal, E. Dayyat, and D. Gozal
Pediatric Obstructive Sleep Apnea: Complications, Management, and Long-term Outcomes
Proceedings of the ATS,
February 15, 2008;
5(2):
274 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Harsch
Metabolic disturbances in patients with obstructive sleep apnoea syndrome
Eur. Respir. Rev.,
December 1, 2007;
16(106):
196 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mokhlesi and A. Tulaimat
Recent Advances in Obesity Hypoventilation Syndrome
Chest,
October 1, 2007;
132(4):
1322 - 1336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. McNicholas
Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2007;
293(4):
R1666 - R1670.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Parati, C. Lombardi, and K. Narkiewicz
Sleep apnea: epidemiology, pathophysiology, and relation to cardiovascular risk
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2007;
293(4):
R1671 - R1683.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. T. McNicholas, M. R. Bonsignore, and the Management Committee of EU COST ACTION B26
Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities
Eur. Respir. J.,
January 1, 2007;
29(1):
156 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Horner and T. D. Bradley
Update in sleep and control of ventilation 2005.
Am. J. Respir. Crit. Care Med.,
April 15, 2006;
173(8):
827 - 832.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Harle, R H Straub, R Wiest, A Mayer, J Scholmerich, F Atzeni, M Carrabba, M Cutolo, and P Sarzi-Puttini
Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems
Ann Rheum Dis,
January 1, 2006;
65(1):
51 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
Copyright © 2005 American Thoracic Society
|
|
|
